Darbepoetin alfa is more potent in vivo and can be administered less frequently than rHuEPO

doi:10.1038/sj.bjc.6600506 www.bjcancer.com © (2002) Cancer Research UK

Detalles Bibliográficos
Autores principales: Egrie, J, Browne, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376125/
http://dx.doi.org/10.1038/sj.bjc.6600506
_version_ 1782154695828045824
author Egrie, J
Browne, J
author_facet Egrie, J
Browne, J
author_sort Egrie, J
collection PubMed
description doi:10.1038/sj.bjc.6600506 www.bjcancer.com © (2002) Cancer Research UK
format Text
id pubmed-2376125
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23761252009-09-10 Darbepoetin alfa is more potent in vivo and can be administered less frequently than rHuEPO Egrie, J Browne, J Br J Cancer Letter to the Editor doi:10.1038/sj.bjc.6600506 www.bjcancer.com © (2002) Cancer Research UK Nature Publishing Group 2002-08-12 /pmc/articles/PMC2376125/ http://dx.doi.org/10.1038/sj.bjc.6600506 Text en Copyright © 2002 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Letter to the Editor
Egrie, J
Browne, J
Darbepoetin alfa is more potent in vivo and can be administered less frequently than rHuEPO
title Darbepoetin alfa is more potent in vivo and can be administered less frequently than rHuEPO
title_full Darbepoetin alfa is more potent in vivo and can be administered less frequently than rHuEPO
title_fullStr Darbepoetin alfa is more potent in vivo and can be administered less frequently than rHuEPO
title_full_unstemmed Darbepoetin alfa is more potent in vivo and can be administered less frequently than rHuEPO
title_short Darbepoetin alfa is more potent in vivo and can be administered less frequently than rHuEPO
title_sort darbepoetin alfa is more potent in vivo and can be administered less frequently than rhuepo
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376125/
http://dx.doi.org/10.1038/sj.bjc.6600506
work_keys_str_mv AT egriej darbepoetinalfaismorepotentinvivoandcanbeadministeredlessfrequentlythanrhuepo
AT brownej darbepoetinalfaismorepotentinvivoandcanbeadministeredlessfrequentlythanrhuepo

Ejemplares similares